Henley Business Angels Member invests in Occuity, a medical device company pioneering advancements in the field of Oculomics

Occuity, a MedTech company developing handheld, non-invasive optical diagnostics, has received investment from a Henley Business Angels member who contributed towards a fundraising round totalling over £5m.

Up until now, the screening and monitoring of some of the greatest healthcare challenges, such as Alzheimer’s Disease, diabetes, and sepsis, have been rooted in invasive, painful blood tests, often requiring large, complex and expensive machines. Furthermore, existing tests can lead to other complications, such as disease transmission or negative side effects.

Occuity’s devices address these problems and, given their handheld, non-contact nature, will allow practitioners to get the information they need from patients more easily and quickly, improving front-line care. With no clinical training required and a lower long-term cost, Occuity’s devices are better, faster and safer than existing tests.

After successful clinical trials and completion of the CE marking process, Occuity’s pachymeter, which supports glaucoma diagnosis, is now being rolled out to its global distributor network. The investment raised during this round is focused on growing sales and scaling up the distribution network, as well as further R&D to expand their product offering.